Authors
CY Cheah, NN Shah, W Jurczak, P Luigi Zinzani, TA Eyre, CS Ujjani, K Izutsu, S Ma, I Flinn, AJ Alencar, D Lewis, K Patel, K Maddocks, Y Wang, T Munir, AD Zelenetz, M Balbas, DE Tsai, C Wang, ML Wang
Publication date
2023/6/2
Journal
Hematological Oncology
Volume
41
Description
Abstract PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS, SUBGROUP ANALYSIS FROM BRUIN WITH > 3 YEARS FOLLOW-UP FROM START OF ENROLLMENT B Introduction: b Pirtobrutinib is a highly selective, non-covalent (reversible) BTK-inhibitor (BTKi).[Extracted from the article]
Copyright of Hematological Oncology is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. Copyright applies to all Abstracts.